LEXARIA BIOSCIENCE CORP. Equity Securities, FV-NI, Unrealized Loss
LEXARIA BIOSCIENCE CORP. (LEXX) reported Equity Securities, FV-NI, Unrealized Loss of $22.09 thousand for the 3-month period ending 2025-11-30, per its 10-Q filed 2026-01-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2026-01-13
- LEXARIA BIOSCIENCE CORP. equity securities, fv-ni, unrealized loss for the quarter ending 2025-11-30 was $22.09K, a 38.67% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. equity securities, fv-ni, unrealized loss for the quarter ending 2024-11-30 was $15.93K.
- LEXARIA BIOSCIENCE CORP. equity securities, fv-ni, unrealized loss for fiscal 2025 was $33.71K, a 51.72% decline from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. equity securities, fv-ni, unrealized loss for fiscal 2024 was $69.83K.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|
| 2025-11-30 | $22.09K 10-Q · filed 2026-01-13 | |
| 2025-08-31 | $33.71K 10-K · filed 2025-11-28 | |
| 2024-11-30 | $15.93K 10-Q · filed 2026-01-13 | |
| 2024-08-31 | $69.83K 10-K · filed 2025-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |